Source:http://linkedlifedata.com/resource/pubmed/id/10783830
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2000-6-26
|
pubmed:abstractText |
The clinical success generally seen in chemotherapy of advanced bladder carcinoma is far from optimal. The mechanism of resistance development is unclear and the expression of P-170 glycoprotein is generally low. The aim of this study, carried out in vitro in sensitive and cisplatin-resistant cell lines, was to examine sensitivity modulation using R-verapamil and cell membrane perturbing agents. Cell growth rates and changes in the order of the cell membrane, determined using electron-paramagnetic resonance spectrometry, were recorded. R-verapamil increased the toxic effect of doxorubicin in the cisplatin-resistant cell line which showed the highest membrane order. Linolenic acid had a similar effect and also increased sensitivity to cisplatin and methotrexate. Bile salts (tauro-cheno-deoxycholate,TCDC, and tauro-urso-deoxycholate TUDC), had little effect on cytotoxicity. These results indicate that R-verapamil and linolenic acid can act as sensitivity modulators in bladder carcinoma cells and that the action of these agents may involve membrane fluidity changes, a phenomenon noted previously in regard to sensitivity modulation in chinese hamster ovary cell lines.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Verapamil
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0946-1965
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
38
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
204-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10783830-Antineoplastic Agents,
pubmed-meshheading:10783830-Calcium Channel Blockers,
pubmed-meshheading:10783830-Carcinoma, Transitional Cell,
pubmed-meshheading:10783830-Cisplatin,
pubmed-meshheading:10783830-Doxorubicin,
pubmed-meshheading:10783830-Drug Resistance, Multiple,
pubmed-meshheading:10783830-Drug Resistance, Neoplasm,
pubmed-meshheading:10783830-Drug Synergism,
pubmed-meshheading:10783830-Electron Spin Resonance Spectroscopy,
pubmed-meshheading:10783830-Humans,
pubmed-meshheading:10783830-Male,
pubmed-meshheading:10783830-Methotrexate,
pubmed-meshheading:10783830-Tumor Cells, Cultured,
pubmed-meshheading:10783830-Urinary Bladder Neoplasms,
pubmed-meshheading:10783830-Verapamil
|
pubmed:year |
2000
|
pubmed:articleTitle |
Cytostatic sensitivity and MDR in bladder carcinoma cells: implications for tumor therapy.
|
pubmed:affiliation |
Klinik für Urologie und Kinderurologie, St. Katharinenhospital Frechen, Germany.
|
pubmed:publicationType |
Journal Article
|